Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if ...

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

Diabetes Care Devices Market Insights, Competitive Landscape, and Market Forecast - 2034” report provides the current ...

Opportunities include integrating digital health for remote care, leveraging demographic trends, and overcoming CGM unit costs to expand access across regionsDublin, March 16, 2026 (GLOBE NEWSWIRE) -- ...

DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult ...

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose ...